HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

About this update from Hcw Biologics Inc.

Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings Panel MIRAMAR, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today announced that its Board of Directors has approved a 1-for-6 reverse stock split of the Company's common stock, par value $0.0001 ("Common Stock"), which will be effective at 12:01 a.m. Eastern Time on June 30, 2026. The Company's Common Stock will be traded on The Nasdaq Capital Market on a reverse split-adjusted basis beginning on June 30, 2026, under the Company's existing trading symbol "HCWB." After an appeal, the Company received a decision letter from a Nasdaq Hearings Panel (the "Panel") on May 29, 2026, which provided a path to compliance with Nasdaq Listing Rule 5550(a) (the "Bid Price Rule"). The primary requirement in the Panel's decision letter was that the Company's Common Stock must trade above $1.00 per share for a period of 20 days prior to July 29, 2026. The Company's Common Stock completed 20 trading days above $1.00 per share as of June 12, 2026, and has continued to trade around $1 per share since that time. Given the Panel's stated requirements, including that the Company maintain compliance with the Bid Price Rule or face immediate delisting, the reverse stock split is intended to ensure compliance with the Bid Price Rule as well as other conditions required by the Panel. The new CUSIP number following the reverse stock split will be 40423R303. The Company filed the relevant amendments to its Certificate of Incorporation with the Delaware Secretary of State on June 24, 2026 to effect the reverse split on June 30, 2026. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest in the Company, except to the extent that the reverse stock split would otherwise result in any of the Company's stockholders owning a fractional share as described in more...

View stock analysis, news, and events for Hcw Biologics Inc.